Kura Oncology Receives Breakthrough Therapy Designation for Ziftomenib in NPM1-Mutant AML
– Ziftomenib is the first investigational treatment to be granted Breakthrough Therapy Designation for NPM1-mutant AML – – Registration-directed trial...
Pharmaceutical
BioCryst to Report First Quarter 2024 Financial Results on May 6
RESEARCH TRIANGLE PARK, N.C., April 22, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will...
SNIPR Biome receives funding from CARB-X to support advancement of CRISPR-medicine SNIPR001 into clinical trials in haematological cancer patients
SNIPR Biome receives funding from CARB-X to support advancement of CRISPR-medicine SNIPR001 into clinical trials in haematological cancer patients Phase...
XORTX Announces Publication of Key Research in ADPKD
CALGARY, Alberta, April 22, 2024 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX...
Centessa Pharmaceuticals Announces Open IND for ORX750; Proof-of-Concept Data in Sleep-Deprived Healthy Volunteers Planned for 2H 2024
BOSTON and LONDON, April 22, 2024 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company that aims...
BioXcel Therapeutics Announces Plan for Evaluating BXCL501 in the At-Home Setting to Expand Its Market Potential
Company plans to initiate SERENITY At-Home pivotal Phase 3 safety trial with 120 mcg dose following recent meeting with FDA...
Plus Therapeutics Receives $3 Million Award Recommendation from the United States Department of Defense
Plus now has $23 million in active awards support for the Company’s targeted radiotherapeutic pipeline Funding for pediatric brain cancer...
Tiziana Life Sciences Announces Additional Clinical Improvements Among Multiple Sclerosis Patients in its Expanded Access Program
70% of Patients in the Expanded Access Program (EAP) Have Seen Measurable Clinical Improvement in Their Fatigue After Six Months...
BioNTech to Report First Quarter 2024 Financial Results and Corporate Update on May 6, 2024
MAINZ, Germany, April 22, 2024 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will announce its financial results for...
Evexta Bio Reports Progress towards Clinical Development of Rupitasertib in Advanced Breast Cancer
Evexta Bio Reports Progress towards Clinical Development of Rupitasertib in Advanced Breast Cancer Feedback from FDA following Type B meeting...
Transactions in Connection with Share Buy-back Program Genmab
Company Announcement COPENHAGEN, Denmark; April 22, 2024 – Genmab A/S (Nasdaq: GMAB). On March 15, 2024, Genmab announced the initiation...
Orion Corporation: Managers’ transactions – Veli-Matti Mattila
ORION CORPORATION MANAGERS’ TRANSACTIONS 22 APRIL 2024 at 9.45 EEST Orion Corporation: Managers’ transactions – Veli-Matti Mattila Orion Corporation has...
SNIPR Biome receives funding from CARB-X to support advancement of CRISPR-medicine SNIPR001 into clinical trials in haematological cancer patients
SNIPR Biome receives funding from CARB-X to support advancement of CRISPR-medicine SNIPR001 into clinical trials in haematological cancer patients Phase...
NLS Pharmaceutics Announces Receipt of Staff Delisting Determination from Nasdaq; Intends to Request Hearing
ZÜRICH, SWITZERLAND / ACCESSWIRE / April 19, 2024 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP)(NASDAQ:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage...
Cosmos Health Receives Nasdaq Notice on Late Filing of Its Form 10-K
CHICAGO, IL / ACCESSWIRE / April 19, 2024 / Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM), a diversified,...
Sunshine Biopharma’s Nora Pharma Receives Health Canada Approval for Niopeg(R), a Biosimilar of Neulasta(R)
NEW YORK, NY / ACCESSWIRE / April 19, 2024 / Sunshine Biopharma Inc. (NASDAQ:SBFM), a pharmaceutical company offering and researching...
Nutriband Inc. Announces $8.4M Private Placement
Nutriband is targeting a 505(b)(2) NDA to the FDA for marketing approval of AVERSA™ Fentanyl in Q1 2025 ORLANDO, FL...
CorMedix Inc. Announces CMS Grants TDAPA to DefenCath
BERKELEY HEIGHTS, N.J., April 19, 2024 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and...
Preliminary Results for the Year Ended 31 December 2023
19 April 2024 Biodexa Pharmaceuticals PLC(“Biodexa” or the “Company” or, together with its subsidiaries, the “Group”) Preliminary Results for the...
Tiziana Life Sciences Announces Study Results from Intranasal Anti-CD3 Foralumab in Multiple Sclerosis Patients with PIRA Highlighted in Neurology Today®
- Intranasal foralumab attenuated microglial activation in patients with non-active secondary progressive multiple sclerosis and progression independent of relapse (PIRA)...